Investor Ideas, Trading Ideas and Stocks to Watch : #AIEye Episode 410: Workday (NasdaqGS: $WDAY) and IBM (NYSE: $IBM) Expand Partnership for Return to Work Solution, Express Inc. (NYSE: $EXPR) Implements #AI-based S5 Assortment

Thursday, August 13, 2020

#AIEye Episode 410: Workday (NasdaqGS: $WDAY) and IBM (NYSE: $IBM) Expand Partnership for Return to Work Solution, Express Inc. (NYSE: $EXPR) Implements #AI-based S5 Assortment

#AIEye Episode 410: Workday (NasdaqGS: $WDAY) and IBM (NYSE: $IBM) Expand Partnership for Return to Work Solution, Express Inc. (NYSE: $EXPR) Implements #AI-based S5 Assortment

Global AI in Drug Discovery Market to See CAGR of 43.24% from 2020-2026

Point Roberts WA, Vancouver BC – August 13, 2020 – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial intelligence.

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2020/081320-AI-Eye.mp3

Read this in full at https://www.investorideas.com/news/2020/artificial-intelligence/08131AIEye-WDAY-IBM.asp

Hear the Ai Eye on Spotify

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (NasdaqGS:WDAY) (NYSE:IBM) (NYSE:EXPR)

Workday, Inc. (NasdaqGS:WDAY) and IBM (NYSE:IBM) announced “an expanded partnership and the availability of a joint solution to help business and community leaders plan, schedule, and monitor a safe return to the workplace for employees.” The two firms’ integrated solution includes Watson Works, described in the press release as “a set of products that embeds Watson artificial intelligence (AI) models and applications to help companies as they navigate many aspects of the return to workplace challenge, including deciding when to return to the workplace, connecting employer data to entry privileges, and managing facilities and adhering to new protocols.” Kareem Yusuf, general manager, AI Applications, IBM Cloud and Cognitive Software, said:

"Keeping employees safe during the return to workplace process is of critical importance to business leaders across industries. By partnering with Workday on a joint solution, we're extending the capabilities delivered by Watson Works to help customers gain greater agility to respond to ever-changing working conditions and evolving business needs. Together we are helping organizations overcome the complexities involved in continuous planning to ultimately improve workplace readiness."

Apparel retailer Express, Inc. (NYSE:EXPR) has partnered with cloud-based AI products company S5 Stratos Inc., and completed the implementation of S5 Assortment, described as “a retail assortment planning application that uses AI and machine learning to track changing consumer demand and predict selling patterns at a hyper-localized level.” Chetan Anand Gabri, CEO and Co-Founder, S5 Stratos, explained:

"A large part of effectively servicing today’s consumer lies in understanding data. As retailers face unprecedented challenges in gaining and holding market share, they need solutions that can quickly read and interpret data, and present relevant insights and recommended actions. S5’s solutions effectively put the power of advanced data science directly into the hands of the end-user, empowering better decisions and greater adaptability, which ultimately forges more agile organizations. By using S5’s AI-driven platform, Express is blazing the trail for modern retail and pioneering a new era of consumer-centric strategies in retail."

Global AI in Drug Discovery Market to See CAGR of 43.24% from 2020-2026

A report published by Research and Markets finds that the global AI in Drug Discovery market, which was valued at $343.78 million in 2020, will exhibit a compound annual growth rate (CAGR) of 43.24 percent in the forecast period 2020-2026. An excerpt from the report’s description reads:

There is a significant increase in the number of applications that focuses on the target and drug discovery, preclinical and clinical development, and post-approval activities. AI can help in improving drug approval rates, reduce development costs, the swift availability of medications and help patients comply with their treatments. The global AI in the drug discovery market has a high demand due to its increasing need to shorten the drug discovery process in order to get drugs faster for treating various incurable and viral diseases. Moreover, AI plays an important role to understand the mechanism of disease by determining biomarkers and creating data or models for the drug discovery process which will ultimately drive the market over the next few years.

Sam Mowers, Investorideas.com

Read and hear other editions of the AI Eye

For a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change , Exploring Mining the AI Eye .

The Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence is an original content brand of Investorideas.com